SPOTLIGHT: Me-too drugs now a tough sell

One of pharma's business strategies may be nearing a dead end. As drug pipelines began to trickle instead of flow, drugmakers turned to tweaking existing drugs as a way to get new products onto the market. But health insurers, who've become ever more vigilant about pushing lower-cost drugs, are getting skeptical, Dow Jones reports. So-called "me too" drugs are about to face a tougher market. Report